JPWO2020145364A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020145364A5 JPWO2020145364A5 JP2020565214A JP2020565214A JPWO2020145364A5 JP WO2020145364 A5 JPWO2020145364 A5 JP WO2020145364A5 JP 2020565214 A JP2020565214 A JP 2020565214A JP 2020565214 A JP2020565214 A JP 2020565214A JP WO2020145364 A5 JPWO2020145364 A5 JP WO2020145364A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- retinal
- pharmaceutical composition
- methyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 208000017442 Retinal disease Diseases 0.000 claims 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000002780 macular degeneration Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims 4
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 claims 4
- 235000019285 ethoxyquin Nutrition 0.000 claims 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 4
- 206010061818 Disease progression Diseases 0.000 claims 3
- 230000005750 disease progression Effects 0.000 claims 3
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- PBZRRADJWNBPNY-XDRMOJKASA-N (3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-ol;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(O)C=C2[C@]3(C)CCN(C)[C@@H]3N(C)C2=C1 PBZRRADJWNBPNY-XDRMOJKASA-N 0.000 claims 2
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 claims 2
- 239000004258 Ethoxyquin Substances 0.000 claims 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 2
- 206010061323 Optic neuropathy Diseases 0.000 claims 2
- 206010057430 Retinal injury Diseases 0.000 claims 2
- 229960004046 apomorphine Drugs 0.000 claims 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims 2
- 201000006754 cone-rod dystrophy Diseases 0.000 claims 2
- HKGWQUVGHPDEBZ-OLZOCXBDSA-N eseroline Chemical compound C1=C(O)C=C2[C@]3(C)CCN(C)[C@@H]3N(C)C2=C1 HKGWQUVGHPDEBZ-OLZOCXBDSA-N 0.000 claims 2
- 229940093500 ethoxyquin Drugs 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229960004569 indapamide Drugs 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- 208000020911 optic nerve disease Diseases 0.000 claims 2
- VGOMWUDYUGKNOE-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-2,3-dihydroindol-6-amine Chemical compound CC1=CC(C)=CC(N2C3=CC(N)=CC=C3CC2)=C1 VGOMWUDYUGKNOE-UHFFFAOYSA-N 0.000 claims 1
- FRYYLQNPYFEVOS-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)indol-6-amine Chemical compound CC1=CC(C)=CC(N2C3=CC(N)=CC=C3C=C2)=C1 FRYYLQNPYFEVOS-UHFFFAOYSA-N 0.000 claims 1
- UYNBONWIZICGNX-UHFFFAOYSA-N 1-(4-methoxyphenyl)indol-6-amine Chemical compound COC1=CC=C(C=C1)N1C=CC2=CC=C(C=C12)N UYNBONWIZICGNX-UHFFFAOYSA-N 0.000 claims 1
- PEXQLAPMEYRICD-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)indol-6-amine Chemical compound CSC1=CC=C(C=C1)N1C=CC2=CC=C(C=C12)N PEXQLAPMEYRICD-UHFFFAOYSA-N 0.000 claims 1
- ZPQBJKNAZFUCAL-UHFFFAOYSA-N 1-[4-(trifluoromethoxy)phenyl]-2,3-dihydroindol-5-amine Chemical compound FC(OC1=CC=C(C=C1)N1CCC2=CC(=CC=C12)N)(F)F ZPQBJKNAZFUCAL-UHFFFAOYSA-N 0.000 claims 1
- -1 3-amino-4-((1-phenylethyl)amino)methylbenzoate Chemical compound 0.000 claims 1
- 208000036443 AIPL1-related retinopathy Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000033810 Choroidal dystrophy Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 231100000111 LD50 Toxicity 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 208000009857 Microaneurysm Diseases 0.000 claims 1
- KMNANZRFPFWSBB-UHFFFAOYSA-N N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide Chemical class S(N)(=O)(=O)C=1C=C(C(=O)NN2C(CC3=CC=CC=C23)C)C=CC=1 KMNANZRFPFWSBB-UHFFFAOYSA-N 0.000 claims 1
- WJQUKFMYSLKUEM-UHFFFAOYSA-N Nc1ccc2n(ccc2c1)-c1ccc(OC(F)(F)F)cc1 Chemical compound Nc1ccc2n(ccc2c1)-c1ccc(OC(F)(F)F)cc1 WJQUKFMYSLKUEM-UHFFFAOYSA-N 0.000 claims 1
- 208000014245 Ocular vascular disease Diseases 0.000 claims 1
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000014139 Retinal vascular disease Diseases 0.000 claims 1
- 206010038903 Retinal vascular occlusion Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 208000014769 Usher Syndromes Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000034700 Vitreous opacities Diseases 0.000 claims 1
- 208000003571 choroideremia Diseases 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000003885 eye ointment Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- JZOQMWIPTWFXCA-UHFFFAOYSA-N methyl 3-amino-4-(3-methoxyanilino)benzoate Chemical compound NC1=CC(C(=O)OC)=CC=C1NC1=CC=CC(OC)=C1 JZOQMWIPTWFXCA-UHFFFAOYSA-N 0.000 claims 1
- LGSBPINARZHJQP-UHFFFAOYSA-N methyl 3-amino-4-(4-methoxyanilino)benzoate Chemical compound NC1=CC(C(=O)OC)=CC=C1NC1=CC=C(OC)C=C1 LGSBPINARZHJQP-UHFFFAOYSA-N 0.000 claims 1
- 229940095102 methyl benzoate Drugs 0.000 claims 1
- 208000012268 mitochondrial disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229940069265 ophthalmic ointment Drugs 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 208000026875 vascular ectasia Diseases 0.000 claims 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024128655A JP2024144702A (ja) | 2019-01-09 | 2024-08-05 | 網膜疾患の治療のための眼内または経口投与用医薬組成物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019001979 | 2019-01-09 | ||
| PCT/JP2020/000538 WO2020145364A1 (ja) | 2019-01-09 | 2020-01-09 | 網膜疾患の治療のための眼内または経口投与用医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024128655A Division JP2024144702A (ja) | 2019-01-09 | 2024-08-05 | 網膜疾患の治療のための眼内または経口投与用医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2020145364A1 JPWO2020145364A1 (https=) | 2020-07-16 |
| JPWO2020145364A5 true JPWO2020145364A5 (https=) | 2023-01-19 |
Family
ID=71520971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565214A Pending JPWO2020145364A1 (https=) | 2019-01-09 | 2020-01-09 | |
| JP2024128655A Pending JP2024144702A (ja) | 2019-01-09 | 2024-08-05 | 網膜疾患の治療のための眼内または経口投与用医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024128655A Pending JP2024144702A (ja) | 2019-01-09 | 2024-08-05 | 網膜疾患の治療のための眼内または経口投与用医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220096410A1 (https=) |
| EP (1) | EP3919052A4 (https=) |
| JP (2) | JPWO2020145364A1 (https=) |
| CN (1) | CN113286581A (https=) |
| AU (1) | AU2020205535B2 (https=) |
| CA (1) | CA3126333A1 (https=) |
| WO (1) | WO2020145364A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3148598A1 (en) | 2019-07-30 | 2021-02-04 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating fibrotic pathologies |
| WO2022164996A1 (en) * | 2021-01-29 | 2022-08-04 | Mayo Foundation For Medical Education And Research | Methods of treating ocular fibrotic pathologies |
| CN113082031A (zh) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用 |
| US20230398095A1 (en) * | 2022-06-10 | 2023-12-14 | Ahmad Alkayali | Therapeutic agent for treatment of age-related macular degeneration |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2771010B1 (fr) * | 1997-11-19 | 2003-08-15 | Adir | Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires |
| CA2548146A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| EP2273988B1 (en) | 2008-04-18 | 2015-09-09 | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona | L-dopa for treating age-related macular degeneration |
| GB0819530D0 (en) * | 2008-10-24 | 2008-12-03 | Univ Sheffield | Methods and compositions |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| WO2015029948A1 (ja) * | 2013-08-26 | 2015-03-05 | リンク・ジェノミクス株式会社 | 網膜色素上皮の障害を原因とする網膜疾患の予防または治療剤 |
| JP2017218384A (ja) * | 2016-06-03 | 2017-12-14 | 国立大学法人京都大学 | 網膜疾患の予防または治療のための医薬組成物 |
| PT3266446T (pt) * | 2016-07-07 | 2019-01-30 | Salvat Lab Sa | Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média |
| US11123411B2 (en) * | 2016-12-08 | 2021-09-21 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
| JP6864327B2 (ja) * | 2017-07-06 | 2021-04-28 | 山田 健一 | 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法 |
-
2020
- 2020-01-09 EP EP20739000.6A patent/EP3919052A4/en active Pending
- 2020-01-09 WO PCT/JP2020/000538 patent/WO2020145364A1/ja not_active Ceased
- 2020-01-09 US US17/422,057 patent/US20220096410A1/en active Pending
- 2020-01-09 JP JP2020565214A patent/JPWO2020145364A1/ja active Pending
- 2020-01-09 AU AU2020205535A patent/AU2020205535B2/en active Active
- 2020-01-09 CN CN202080008302.7A patent/CN113286581A/zh active Pending
- 2020-01-09 CA CA3126333A patent/CA3126333A1/en active Pending
-
2024
- 2024-08-05 JP JP2024128655A patent/JP2024144702A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020145364A5 (https=) | ||
| CA2674080C (en) | Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof | |
| US9161923B2 (en) | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease | |
| EP3348260B1 (en) | Pharmaceutical tramadol composition for ophthalmic use | |
| EP3318280A1 (en) | Depot preparation containing citric acid ester | |
| CN107427460A (zh) | 溴莫尼定和噻吗洛尔的固定剂量组合 | |
| US20090239836A1 (en) | Multifunctional Ophthalmic Compositions | |
| AU2020205535B2 (en) | Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases | |
| KR102622656B1 (ko) | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 | |
| KR20250026365A (ko) | 점안제 | |
| PL208284B1 (pl) | Pochodne benzo[g]chinoliny, kompozycje je zawierające oraz zastosowanie takich pochodnych | |
| FI3720428T3 (fi) | Dobesiliinihappoa käsittävä oftalminen paikalliskoostumus silmän takasegmentin sairauksien hoitoon | |
| US20110160172A1 (en) | Fluoroquinolone derivatives for ophthalmic applications | |
| US20240033246A1 (en) | Compounds for treating eye diseases and disorders | |
| PL215012B1 (pl) | Nowe pochodne benzo[g]chinoliny, kompozycje farmaceutyczne je zawierajace oraz zastosowania farmaceutyczne tych zwiazków | |
| US8268824B2 (en) | Therapeutic agent for corneal disease | |
| JP7829678B2 (ja) | 神経変性眼疾患を治療するためのプリドピジン及びその類似体 | |
| KR102175743B1 (ko) | 피나플록사신 현탁 조성물 | |
| JP2008530202A (ja) | 改良薬剤組成物 | |
| US20110224200A1 (en) | Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde 0-(piperidin-1-yl-propyl)-oxime derivative as active ingredient | |
| ES2377342T3 (es) | Remedio para enfermedades corneales | |
| AU2025217391A1 (en) | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease | |
| CN117460501A (zh) | 用于退行性视网膜疾病的trpa1通道拮抗剂化合物 | |
| US20170202845A1 (en) | Prophylactic or therapeutic agent for a posterior ocular disease |